RU2008148941A - 4-[(3-фторфенокси)фенилметил]пиперидин метансульфонат, применение, способ синтеза и фармацевтические композиции - Google Patents
4-[(3-фторфенокси)фенилметил]пиперидин метансульфонат, применение, способ синтеза и фармацевтические композиции Download PDFInfo
- Publication number
- RU2008148941A RU2008148941A RU2008148941/04A RU2008148941A RU2008148941A RU 2008148941 A RU2008148941 A RU 2008148941A RU 2008148941/04 A RU2008148941/04 A RU 2008148941/04A RU 2008148941 A RU2008148941 A RU 2008148941A RU 2008148941 A RU2008148941 A RU 2008148941A
- Authority
- RU
- Russia
- Prior art keywords
- fluorophenoxy
- phenylmethyl
- piperidine
- methanesulfonic acid
- salt
- Prior art date
Links
- ZEFXAHXKTLEBQA-UHFFFAOYSA-N 4-[(3-fluorophenoxy)-phenylmethyl]piperidine;methanesulfonic acid Chemical compound CS(O)(=O)=O.FC1=CC=CC(OC(C2CCNCC2)C=2C=CC=CC=2)=C1 ZEFXAHXKTLEBQA-UHFFFAOYSA-N 0.000 title claims abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract 3
- 238000001308 synthesis method Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 10
- 150000003839 salts Chemical class 0.000 claims abstract 10
- 239000000651 prodrug Substances 0.000 claims abstract 8
- 229940002612 prodrug Drugs 0.000 claims abstract 8
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims abstract 8
- 239000012453 solvate Substances 0.000 claims abstract 8
- 239000000203 mixture Substances 0.000 claims abstract 6
- 208000015114 central nervous system disease Diseases 0.000 claims abstract 5
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims abstract 4
- ZEFXAHXKTLEBQA-FERBBOLQSA-N 4-[(r)-(3-fluorophenoxy)-phenylmethyl]piperidine;methanesulfonic acid Chemical compound CS(O)(=O)=O.FC1=CC=CC(O[C@H](C2CCNCC2)C=2C=CC=CC=2)=C1 ZEFXAHXKTLEBQA-FERBBOLQSA-N 0.000 claims abstract 4
- ZEFXAHXKTLEBQA-GMUIIQOCSA-N 4-[(s)-(3-fluorophenoxy)-phenylmethyl]piperidine;methanesulfonic acid Chemical compound CS(O)(=O)=O.FC1=CC=CC(O[C@@H](C2CCNCC2)C=2C=CC=CC=2)=C1 ZEFXAHXKTLEBQA-GMUIIQOCSA-N 0.000 claims abstract 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims abstract 4
- 201000010099 disease Diseases 0.000 claims abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 4
- 239000003814 drug Substances 0.000 claims abstract 4
- 238000004519 manufacturing process Methods 0.000 claims abstract 4
- 230000001404 mediated effect Effects 0.000 claims abstract 4
- 229960002748 norepinephrine Drugs 0.000 claims abstract 4
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims abstract 4
- 229940076279 serotonin Drugs 0.000 claims abstract 4
- FDHPZDXAAGIHFC-UHFFFAOYSA-N 4-[(3-fluorophenoxy)-phenylmethyl]piperidine Chemical compound FC1=CC=CC(OC(C2CCNCC2)C=2C=CC=CC=2)=C1 FDHPZDXAAGIHFC-UHFFFAOYSA-N 0.000 claims abstract 2
- 208000007848 Alcoholism Diseases 0.000 claims abstract 2
- 208000019901 Anxiety disease Diseases 0.000 claims abstract 2
- 206010006550 Bulimia nervosa Diseases 0.000 claims abstract 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims abstract 2
- 208000002193 Pain Diseases 0.000 claims abstract 2
- 230000036506 anxiety Effects 0.000 claims abstract 2
- 239000003937 drug carrier Substances 0.000 claims abstract 2
- 229940098779 methanesulfonic acid Drugs 0.000 claims abstract 2
- 238000011321 prophylaxis Methods 0.000 claims abstract 2
- 238000011282 treatment Methods 0.000 claims abstract 2
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010036618 Premenstrual syndrome Diseases 0.000 claims 1
- 206010041250 Social phobia Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 201000007930 alcohol dependence Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Addiction (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
1. Соль метансульфоновой кислоты 4-[(3-фторфенокси)фенилметил]пиперидина формулы I, ! ! ее энантиомеры или их смеси или пролекарство или их сольват. ! 2. Соль метансульфоновой кислоты (S)-4-[(3-фторфенокси)фенилметил]пиперидина или пролекарство или их сольват. ! 3. Соль метансульфоновой кислоты (R)-4-[(3-фторфенокси)фенилметил]пиперидина или пролекарство или их сольват. ! 4. Соединение по п.1 в виде смеси соли метансульфоновой кислоты (S)-4-[(3-фторфенокси)фенилметил]пиперидина и соли метансульфоновой кислоты (R)-4-[(3-фторфенокси)фенилметил]пиперидина или пролекарство или их сольват. ! 5. Способ получения соединения, которое определено в любом из пп.1-4, включающий стадии взаимодействия метансульфоновой кислоты и 4-[(3-фторфенокси)фенилметил]пиперидина, его энантиомеров или их смесей. ! 6. Фармацевтическая композиция, содержащая соединение, которое определено в любом из пп.1-4, и по меньшей мере один фармацевтически приемлемый носитель. ! 7. Соединение, которое определено в любом из пп.1-4 для применения в качестве лекарственного средства. ! 8. Применение соединения, которое определено в любом из пп.1-4, в производстве лекарственного средства для лечения и/или профилактики заболевания и/или состояния, опосредуемого серотонином и/или норэпинефрином. ! 9. Применение по п.8, где указанное заболевание и/или состояние, опосредуемое серотонином и/или норэпинефрином, представляет собой заболевание центральной нервной системы. ! 10. Применение по п.9, где указанное заболевание центральной нервной системы выбрано из ряда, включающего: нервную булимию, алкогольную зависимость, тревогу, обсессивно-компульсивное расстройство, панику, боль, предменст
Claims (11)
1. Соль метансульфоновой кислоты 4-[(3-фторфенокси)фенилметил]пиперидина формулы I,
ее энантиомеры или их смеси или пролекарство или их сольват.
2. Соль метансульфоновой кислоты (S)-4-[(3-фторфенокси)фенилметил]пиперидина или пролекарство или их сольват.
3. Соль метансульфоновой кислоты (R)-4-[(3-фторфенокси)фенилметил]пиперидина или пролекарство или их сольват.
4. Соединение по п.1 в виде смеси соли метансульфоновой кислоты (S)-4-[(3-фторфенокси)фенилметил]пиперидина и соли метансульфоновой кислоты (R)-4-[(3-фторфенокси)фенилметил]пиперидина или пролекарство или их сольват.
5. Способ получения соединения, которое определено в любом из пп.1-4, включающий стадии взаимодействия метансульфоновой кислоты и 4-[(3-фторфенокси)фенилметил]пиперидина, его энантиомеров или их смесей.
6. Фармацевтическая композиция, содержащая соединение, которое определено в любом из пп.1-4, и по меньшей мере один фармацевтически приемлемый носитель.
7. Соединение, которое определено в любом из пп.1-4 для применения в качестве лекарственного средства.
8. Применение соединения, которое определено в любом из пп.1-4, в производстве лекарственного средства для лечения и/или профилактики заболевания и/или состояния, опосредуемого серотонином и/или норэпинефрином.
9. Применение по п.8, где указанное заболевание и/или состояние, опосредуемое серотонином и/или норэпинефрином, представляет собой заболевание центральной нервной системы.
10. Применение по п.9, где указанное заболевание центральной нервной системы выбрано из ряда, включающего: нервную булимию, алкогольную зависимость, тревогу, обсессивно-компульсивное расстройство, панику, боль, предменструальный синдром, социальную фобию, депрессию и профилактику мигрени.
11. Применение по п.10, где указанное заболевание центральной нервной системы представляет собой депрессию.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06380112.0 | 2006-05-12 | ||
| EP06380112A EP1854785A1 (en) | 2006-05-12 | 2006-05-12 | 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions |
| US11/486,350 | 2006-07-13 | ||
| US11/486,350 US20070265306A1 (en) | 2006-05-12 | 2006-07-13 | 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2008148941A true RU2008148941A (ru) | 2010-06-20 |
| RU2412169C2 RU2412169C2 (ru) | 2011-02-20 |
Family
ID=37061190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008148941/04A RU2412169C2 (ru) | 2006-05-12 | 2007-04-12 | 4-[(3-фторфенокси)фенилметил]пиперидин метансульфонат:применение, способ синтеза и фармацевтические композиции |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20070265306A1 (ru) |
| EP (2) | EP1854785A1 (ru) |
| JP (1) | JP2009536962A (ru) |
| KR (1) | KR20090009971A (ru) |
| CN (1) | CN101443312B (ru) |
| AT (1) | ATE501121T1 (ru) |
| AU (1) | AU2007251663B2 (ru) |
| BR (1) | BRPI0710856A2 (ru) |
| CA (1) | CA2651933A1 (ru) |
| CY (1) | CY1111460T1 (ru) |
| DE (1) | DE602007013040D1 (ru) |
| DK (1) | DK2032534T3 (ru) |
| ES (1) | ES2362683T3 (ru) |
| HR (1) | HRP20110333T1 (ru) |
| MX (1) | MX2008014439A (ru) |
| MY (1) | MY148406A (ru) |
| NO (1) | NO20085052L (ru) |
| NZ (1) | NZ572714A (ru) |
| PL (1) | PL2032534T3 (ru) |
| RS (1) | RS51858B (ru) |
| RU (1) | RU2412169C2 (ru) |
| SI (1) | SI2032534T1 (ru) |
| WO (1) | WO2007131846A1 (ru) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1854785A1 (en) * | 2006-05-12 | 2007-11-14 | Faes Farma, S.A. | 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions |
| TWI438190B (zh) * | 2008-07-24 | 2014-05-21 | Theravance Inc | ３－（苯氧基苯基甲基）吡咯啶化合物 |
| US20100267743A1 (en) * | 2009-04-15 | 2010-10-21 | Stangeland Eric L | 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds |
| MX2012000685A (es) | 2009-07-13 | 2012-02-28 | Theravance Inc | Compuesto de 3-fenoximetilpirrolidina. |
| WO2011011231A1 (en) * | 2009-07-21 | 2011-01-27 | Theravance, Inc. | 3-phenoxymethylpyrrolidine compounds |
| WO2012051103A1 (en) | 2010-10-11 | 2012-04-19 | Theravance, Inc. | Serotonin reuptake inhibitors |
| WO2012075239A1 (en) | 2010-12-03 | 2012-06-07 | Theravance, Inc. | Serotonin reuptake inhibitors |
| US9002322B2 (en) * | 2011-09-29 | 2015-04-07 | Apple Inc. | Authentication with secondary approver |
| CN104887675B (zh) * | 2014-03-05 | 2018-08-07 | 江苏恩华药业股份有限公司 | [(芳氧基)(杂芳基)]甲基哌啶衍生物在制备治疗抑郁症的药物中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1203149A (en) * | 1968-06-10 | 1970-08-26 | Ici Ltd | Piperidine derivatives |
| ES2157148B1 (es) * | 1998-11-18 | 2002-03-01 | Faes Fabrica Espanola De Produ | Nuevas piperidinas 4-sustituidas. |
| US6518284B2 (en) * | 1998-11-18 | 2003-02-11 | Faes, Fabrica Espanola De Productos Quimicos Y Farmaceuticos S.A. | 4-substituted piperidines |
| AP2006003771A0 (en) * | 2004-04-30 | 2006-10-31 | Warner Lambert Co | Substituted morpholine compounds for the treatmentof central nervous system disorders |
| EP1854785A1 (en) * | 2006-05-12 | 2007-11-14 | Faes Farma, S.A. | 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions |
-
2006
- 2006-05-12 EP EP06380112A patent/EP1854785A1/en not_active Withdrawn
- 2006-07-13 US US11/486,350 patent/US20070265306A1/en not_active Abandoned
-
2007
- 2007-04-12 MY MYPI20084507A patent/MY148406A/en unknown
- 2007-04-12 CA CA002651933A patent/CA2651933A1/en not_active Abandoned
- 2007-04-12 AU AU2007251663A patent/AU2007251663B2/en not_active Ceased
- 2007-04-12 EP EP07728049A patent/EP2032534B1/en active Active
- 2007-04-12 MX MX2008014439A patent/MX2008014439A/es active IP Right Grant
- 2007-04-12 NZ NZ572714A patent/NZ572714A/en not_active IP Right Cessation
- 2007-04-12 SI SI200730543T patent/SI2032534T1/sl unknown
- 2007-04-12 BR BRPI0710856-7A patent/BRPI0710856A2/pt not_active IP Right Cessation
- 2007-04-12 ES ES07728049T patent/ES2362683T3/es active Active
- 2007-04-12 US US12/299,907 patent/US20100004283A1/en not_active Abandoned
- 2007-04-12 CN CN2007800172665A patent/CN101443312B/zh not_active Expired - Fee Related
- 2007-04-12 KR KR1020087030170A patent/KR20090009971A/ko not_active Ceased
- 2007-04-12 RU RU2008148941/04A patent/RU2412169C2/ru not_active IP Right Cessation
- 2007-04-12 HR HR20110333T patent/HRP20110333T1/hr unknown
- 2007-04-12 WO PCT/EP2007/053582 patent/WO2007131846A1/en not_active Ceased
- 2007-04-12 RS RS20110154A patent/RS51858B/sr unknown
- 2007-04-12 PL PL07728049T patent/PL2032534T3/pl unknown
- 2007-04-12 AT AT07728049T patent/ATE501121T1/de active
- 2007-04-12 DK DK07728049.3T patent/DK2032534T3/da active
- 2007-04-12 DE DE602007013040T patent/DE602007013040D1/de active Active
- 2007-04-12 JP JP2009510383A patent/JP2009536962A/ja not_active Ceased
-
2008
- 2008-12-04 NO NO20085052A patent/NO20085052L/no not_active Application Discontinuation
-
2011
- 2011-05-17 CY CY20111100477T patent/CY1111460T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2007251663A1 (en) | 2007-11-22 |
| SI2032534T1 (sl) | 2011-06-30 |
| HRP20110333T1 (hr) | 2011-06-30 |
| CN101443312A (zh) | 2009-05-27 |
| MX2008014439A (es) | 2009-01-21 |
| US20100004283A1 (en) | 2010-01-07 |
| CY1111460T1 (el) | 2015-08-05 |
| NZ572714A (en) | 2010-08-27 |
| BRPI0710856A2 (pt) | 2011-05-17 |
| MY148406A (en) | 2013-04-30 |
| NO20085052L (no) | 2008-12-04 |
| RU2412169C2 (ru) | 2011-02-20 |
| DK2032534T3 (da) | 2011-04-26 |
| RS51858B (sr) | 2012-02-29 |
| PL2032534T3 (pl) | 2011-08-31 |
| DE602007013040D1 (de) | 2011-04-21 |
| EP2032534A1 (en) | 2009-03-11 |
| CN101443312B (zh) | 2011-07-06 |
| EP2032534B1 (en) | 2011-03-09 |
| ES2362683T3 (es) | 2011-07-11 |
| US20070265306A1 (en) | 2007-11-15 |
| CA2651933A1 (en) | 2007-11-22 |
| ATE501121T1 (de) | 2011-03-15 |
| KR20090009971A (ko) | 2009-01-23 |
| HK1130053A1 (en) | 2009-12-18 |
| AU2007251663B2 (en) | 2012-04-05 |
| WO2007131846A1 (en) | 2007-11-22 |
| EP1854785A1 (en) | 2007-11-14 |
| JP2009536962A (ja) | 2009-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008148941A (ru) | 4-[(3-фторфенокси)фенилметил]пиперидин метансульфонат, применение, способ синтеза и фармацевтические композиции | |
| CN107485612B (zh) | 咪唑并吡啶化合物及其用途 | |
| KR101861942B1 (ko) | 신경 발생을 자극할 수 있는 n-페닐-락탐 유도체 및 이의 신경 장애 치료에서의 용도 | |
| JP5349305B2 (ja) | 脊髄性筋萎縮症のための２，４−ジアミノキナゾリン | |
| MY139454A (en) | 4-(aminomethyl)-piperidine benzamides as 5ht4-antagonists | |
| JP2004507527A5 (ru) | ||
| CN105792821B (zh) | 包含1-茚满硫酰胺衍生物的疼痛治疗剂和/或预防剂 | |
| DE69323322T2 (de) | Verwendung dimethylbenzofuran und dimethylbenzopyran derivate als 5-ht3 antagoniste | |
| JP2024514366A (ja) | 可溶性エポキシドヒドロラーゼ阻害剤としてのピペリジン尿素誘導体 | |
| UA102087C2 (en) | 3-sulfonyl-pyrazolo[1,5-a] pyrimidines/antagonists of serotonin 5-ht6receptors, methods for the production and the use thereof | |
| CY1107097T1 (el) | 5ht4-ανταγωνιστικα βενζαμιδια 4-( αμινομεθυλ) - πιπεριδινης | |
| BRPI0517734A (pt) | derivados de 1-[(6,7-alcoxiquinoxalinil substituìdo) aminocarbonil]-4- (hetero) arilpiperazina | |
| KR20110049866A (ko) | 피페리딘-4-아세트아미드 유도체 및 모노아민 신경전달물질 재흡수 억제제로서의 이의 용도 | |
| EA201000832A1 (ru) | Замещённые 3-гидроксипиридины и содержащие их фармацевтические композиции | |
| DE60313143T2 (de) | Verbindungen mit affinität zu rezeptoren des 5ht-1-typs und deren verwendung in der therapie von erkrankungen des zns | |
| KR20100099697A (ko) | 4-[2,3-디플루오로-6-(2-플루오로-4-메틸-페닐술파닐)-페닐]-피페리딘 | |
| RU2006129642A (ru) | Производные алкилминотиазола, их получение и их применение в терапии | |
| CN101906085A (zh) | 治疗心脑血管疾病的化合物、组合物、制备方法及用途 | |
| EA200600057A1 (ru) | Бензамиды 4-(аминометил) пиперидина, замещённого гидроксикарбонилфенилом, в качестве антагонистов 5нт-рецепторов | |
| HK1130053B (en) | 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions | |
| EA200600059A1 (ru) | Гетероциклические замещённые 4-(аминометил) пиперидин бензамиды в качестве 5-нт-антагонистов | |
| TH107354A (th) | อนุพันธ์ของสไปโร-พิเพอริดีน | |
| CN103772425A (zh) | 硅杂哌啶衍生物及其制备方法与用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20130413 |